Trogenix

KiraGen

KiraGen develops multiplex gene-edited CAR-T cell therapies and an AI-driven drug discovery platform for patients with hard-to-treat solid tumours and glioblastoma.

KiraGen Bio

This biotechnology company develops gene-edited cell therapies to treat solid tumours for patients with glioblastoma and other cancers.

Kindling Bio

This company develops a gene therapy platform that engineers tumour cells to display markers for the immune system to treat children with solid tumours.

Synthetic biology-powered mRNA therapeutics

The company develops programmable mRNA therapies using synthetic biology genetic circuits to deliver precise treatments for patients with cancer and other complex diseases.

Glionova AB

Glionova AB develops orally available oncolytic small molecules to treat glioblastoma and other aggressive cancers for patients with high unmet medical needs.

Siren Bio

This company develops immuno-gene therapies combining viral gene delivery and cytokine immunotherapy to treat solid tumours for cancer patients.

TILT Biotherapeutics

This company develops oncolytic viral immunotherapies to treat patients with solid tumours by enhancing immune system responses against cancer cells.

THERAtRAME

The company develops small molecule inhibitors targeting tRNA epitranscriptomics to treat resistant and immune-refractory cancers for patients with limited therapeutic options.